Literature DB >> 23574441

Lipid transmitter signaling as a new target for treatment of cocaine addiction: new roles for acylethanolamides and lysophosphatidic acid.

Laura Orio1, Francisco Javier Pavón, Eduardo Blanco, Antonia Serrano, Pedro Araos, María Pedraz, Patricia Rivera, Montserrat Calado, Juan Suárez, Fernando Rodríguez de Fonseca.   

Abstract

This review analyzes the roles of lipid transmitters, especially those derived from the cleavage of membrane phospholipids, in cocaine-associated behaviors. These lipid signals are important modulators of information processing in the brain, affecting transmitter release, neural plasticity, synaptogenesis, neurogenesis, and cellular energetics. This broad range of actions makes them suitable targets for pharmaceutical development of cocaine addiction therapies because they participate in the main cellular processes underlying the neuroadaptations associated with chronic use of this psychostimulant. The main lipid transmitters reviewed here include a) acylethanolamides and acylglycerols acting on cannabinoid receptors, such as anandamide and 2-arachidonoylglycerol; b) acylethanolamides that do not act on cannabinoid receptors, such as oleoylethanolamide; c) eicosanoids derived from arachidonic acid, including prostaglandins; and d) lysophosphatidic acid, focusing on the role of its LPA-1 receptor. Direct experimental evidence for the significance of these lipids in cocaine-related behaviors is presented and discussed. Additionally, the roles for both their biosynthesis and degradation pathways, as well as the participation of their receptors, are examined. Overall, lipid transmitter signaling can offer new targets for the development of therapies for cocaine addiction.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23574441     DOI: 10.2174/138161281940131209143421

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  6 in total

1.  Sex Differences in Plasma Lysophosphatidic Acid Species in Patients with Alcohol and Cocaine Use Disorders.

Authors:  María Flores-López; Nuria García-Marchena; Pedro Araos; Nerea Requena-Ocaña; Oscar Porras-Perales; Sandra Torres-Galván; Juan Suarez; Nieves Pizarro; Rafael de la Torre; Gabriel Rubio; Juan Jesús Ruiz-Ruiz; Fernando Rodríguez de Fonseca; Antonia Serrano; Francisco Javier Pavón-Morón
Journal:  Brain Sci       Date:  2022-04-30

2.  Systemic administration of oleoylethanolamide protects from neuroinflammation and anhedonia induced by LPS in rats.

Authors:  Aline Sayd; María Antón; Francisco Alén; Javier Rubén Caso; Javier Pavón; Juan Carlos Leza; Fernando Rodríguez de Fonseca; Borja García-Bueno; Laura Orio
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-28       Impact factor: 5.176

3.  Oleoylethanolamide Modulates BDNF-ERK Signaling and Neurogenesis in the Hippocampi of Rats Exposed to Δ9-THC and Ethanol Binge Drinking During Adolescence.

Authors:  Daniel Silva-Peña; Patricia Rivera; Francisco Alén; Antonio Vargas; Leticia Rubio; Nuria García-Marchena; Francisco Javier Pavón; Antonia Serrano; Fernando Rodríguez de Fonseca; Juan Suárez
Journal:  Front Mol Neurosci       Date:  2019-04-24       Impact factor: 5.639

4.  Lipidomic changes in the rat hippocampus following cocaine conditioning, extinction, and reinstatement of drug-seeking.

Authors:  Sumitra Pati; Peggi Angel; Richard R Drake; John J Wagner; Brian S Cummings
Journal:  Brain Behav       Date:  2019-11-07       Impact factor: 2.708

Review 5.  Oleoylethanolamide, Neuroinflammation, and Alcohol Abuse.

Authors:  Laura Orio; Francisco Alen; Francisco Javier Pavón; Antonia Serrano; Borja García-Bueno
Journal:  Front Mol Neurosci       Date:  2019-01-09       Impact factor: 5.639

6.  Revealing Metabolic Perturbation Following Heavy Methamphetamine Abuse by Human Hair Metabolomics and Network Analysis.

Authors:  Suji Kim; Won-Jun Jang; Hyerim Yu; Jihyun Kim; Sang-Ki Lee; Chul-Ho Jeong; Sooyeun Lee
Journal:  Int J Mol Sci       Date:  2020-08-21       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.